Expert Interviews

CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.

Panelists discuss the vital role of primary care providers in early skin cancer detection, highlighting the need for improved diagnostic confidence, integration of artificial intelligence (AI) tools, and efficient workflows to overcome time and resource constraints, ultimately aiming to reduce delays and improve patient outcomes.

Atopic dermatitis is not just "another rash on the schedule. It could the the reason that patient doesn't leave the house."

RAD 2025: Multidisciplinary collaboration at disease-specific meetings drives clinical and therapeutic progress in AD, Dr Yu told Patient Care.

Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.

At RAD 2025, Dr Yu shared hopes for more real-world data and targeted treatment approaches for chronic hand eczema.

RAD 2025: Yale dermatologist Mona Shahriari, MD, urged primary care clinicians to refer patients with AD who don't improve to prevent cumulative emotional burden.

RAD 2025: Expert insights on the psychosocial burden of AD, flexible dosing, and cross-specialty collaboration in pediatric care.

RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.

RAD 2025: Brad Glick, DO, MPH, discusses the intensity of TSW symptoms and cautions against assuming there is mental health disturbance at work.